NCT05495100

A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma

A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with chidamide and azacitidine in the treatment of relapsed and refractory peripheral T-cell lymphoma

Conditions

• Peripheral T Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Mitoxantrone liposome、Chidamide、Azacitidine	Mitoxantrone liposome 20mg/m2, d1; Chidamide 20mg, biw; Azacitidine 100mg, d1\~7; Every 4 weeks is a cycle, with a maximum of 4 cycles of treatment.

Timeline

• Start date: 2022-08-11
• Primary completion: 2023-08-11
• Completion: 2024-08-11
• First posted: 2022-08-10
• Last updated: 2022-08-10

Locations

1 site across 1 country: China